Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1203560

	registered interest
	date	15/06/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	Her Majesty's Government what assessment they have made about whether any drugs or medicines will be in short supply after the UK leaves the EU.
	tabling member printed	Lord Roberts of Llandudno
	uin	HL5715
	answer	answer is ministerial correction date of answer 30/06/2020 answer text <p>The United Kingdom left the European Union on 31 January and is now in a Transition Period until 31 December 2020. During this time, it remains our objective to negotiate a future relationship with the EU and in our respective published negotiating documents, we have both stated objectives to reach an agreement on trade in goods. The UK’s published approach sets out how we want to facilitate trade in medicinal products and support high levels of patient safety.</p><p>The Government, pharmaceutical industry and National Health Service will always work closely together to help ensure patients continue to have access, to the medicines and treatments they need, including insulin, under all scenarios.</p><p>The Department has well-established procedures to deal with medicine shortages and is working closely with industry, the NHS and others in the supply chain to reduce the likelihood of future shortages resulting from any cause.</p><p> </p> answering member printed Lord Bethell grouped question UIN HL5713 question first answered 30/06/2020 15:47:39 answering member 4708 label Biography information for Lord Bethell
	tabling member	3691 label Biography information for Lord Roberts of Llandudno

1186624

	registered interest
	date	19/03/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to manufacture more active pharmaceutical ingredients in the UK to prevent medicine shortages.
	tabling member constituency	Coventry North West
	tabling member printed	Taiwo Owatemi
	uin	32261
	answer	answer is ministerial correction date of answer 14/04/2020 answer text <p>The Government has no plans to create facilities in the United Kingdom to manufacture further active pharmaceutical ingredients. There are 16,000 medicines on the market in the UK. Whilst some of these are manufactured in the UK, most are manufactured abroad. Where medicines are manufactured here, the active ingredients and excipients for those medicines may be manufactured abroad. It is not realistic to manufacture all 16,000 medicines and the active ingredients and excipients needed for these medicines in the UK.</p><p>The production of medicines is complex and highly regulated, and materials and processes must meet rigorous safety and quality standards. Supply problems can affect a wide range of medicines and can arise for various reasons, such as manufacturing issues, problems with the raw ingredients and batch failures. These problems arise regardless of where in the world the manufacture takes place.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 14/04/2020 14:50:24 answering member 4380 label Biography information for Jo Churchill previous answer version 14443 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4779 label Biography information for Taiwo Owatemi

1027714

	registered interest
	date	18/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer on 11 September to Question number 169109 on Social Care: Drugs, (a) when the 2019-20 planning process was completed and (b) what the level of funding is for the 2019-20 prioritisation process.
	tabling member constituency	Alyn and Deeside
	tabling member printed	Mark Tami
	uin	203288
	answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>The independently chaired Clinical Priorities Advisory Group met in November 2018 to make prioritisation recommendations for investments in specialised service for the 2019/20 financial year. Final investment decisions will be announced shortly. A second prioritisation round for investment in 2019/20 will be held next year.</p><p> </p><p>The baseline budget for prioritisation in 2019/20 has been set at £25.7 million reflecting a 2.7% increase on the 2018/19 budget. The availability of any additional funding to support prioritisation will be kept under review between now and May/June 2019 when the second round of investment decisions will be taken for the 2019/20 financial year.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/12/2018 15:58:15 answering member 4067 label Biography information for Steve Brine
	tabling member	1383 label Biography information for Mark Tami

964339

	registered interest
	date	03/09/2018
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, if his Department will make an assessment of the potential merits of reclassifying (a) GHB (b) GHL as a Class A substance.
	tabling member constituency	Brighton, Kemptown
	tabling member printed	Lloyd Russell-Moyle
	uin	169718
	answer	answer is ministerial correction date of answer 26/09/2018 answer text <p>GHB and GBL are controlled as class C drugs under the Misuse of Drugs Act 1971. As with all controlled drugs we will continue to monitor their impact and the potential merits of reclassification.</p><p> </p> answering member constituency Louth and Horncastle answering member printed Victoria Atkins question first answered 26/09/2018 12:17:02 answering member 4399 label Biography information for Victoria Atkins
	tabling member	4615 label Biography information for Lloyd Russell-Moyle

964503

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what funding his Department plans to allocate to products undergoing review by the NHS England relative prioritisation process in 2019-20.
	tabling member constituency	Alyn and Deeside
	tabling member printed	Mark Tami
	uin	169109
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The level of funding for products undergoing review by NHS England will be determined during the 2019/20 planning process.</p><p> </p><p>In 2016/17 and 2017/18, £25 million was set aside for discretionary investment in new specialised services. This was determined by NHS England, who considered it an appropriate level of investment in the context of NHS England’s Specialised Commissioning functioning having to achieve overall efficiency savings of approximately 2.5% and 2.7% in 2016/17 and 2017/18 respectively in order to meet the financial pressures resulting from demographic growth and the legal requirement to fund all positive National Institute for Health and Care Excellence technology appraisals.</p><p> </p><p>The split in the overall funding available between the November and May prioritisation rounds is not fixed but determined each year based on the number and estimated cost of treatments being considered by the independently chaired Clinical Priorities Advisory Group (CPAG) in each round. Revealing the split risks revealing commercial in confidence information around pricing. Anything that is not prioritised in the November round has the opportunity to be considered at the May round therefore ensuring consideration against the full funding envelope for the financial year.</p><p> </p><p>Where manufacturers have requested the cover sheets of the policy propositions, they have received the CPAG summary report as presented at the May 2018 meeting from NHS England.</p><p> </p><p>The full scoring methodology that is used at all prioritisation meetings is published on the NHS England website. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf" target="_blank">https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf</a></p><p> </p><p>The outcome of the May 2018 prioritisation process through use of this methodology has been published as a ranked list of five prioritisation Levels. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/" target="_blank">https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/</a></p><p> </p><p>The impact assessments for all the treatments include a narrative about the estimated forecast financial implications for each item, based on the list price. These are published as part of the public consultation pack. The detailed costings are not shared as in many cases these are based on discount prices provided on a commercial in confidence basis.</p><p> </p><p>The methodology for relative prioritisation has been subject to legal advice as part of its development and implementation, and NHS England believes it complies with equalities legislation, the NHS Constitution and human rights legislation.</p><p> </p><p>NHS England routinely publishes the stakeholder engagement response report as part of consultation through policy development, but does not routinely publish any responses that arise as a result of public consultation.</p><p> </p><p>NHS England has no plans to introduce a revised decision-making process for ultra-orphan medicines as introduced in Scotland following the Montgomery Review. NHS England will continue to use the methodology for prioritisation that has previously been publicly consulted on.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 169110 169111 169112 169113 169114 169115 169116 169117 169118 question first answered 11/09/2018 16:26:10 answering member 4067 label Biography information for Steve Brine
	tabling member	1383 label Biography information for Mark Tami

964504

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what proportion of the funding allocated for 2018-19 for products approved by the relative prioritisation process was allocated to products approved for use in the (a) November 2017 and (b) May 2018 commissioning rounds.
	tabling member constituency	Alyn and Deeside
	tabling member printed	Mark Tami
	uin	169110
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The level of funding for products undergoing review by NHS England will be determined during the 2019/20 planning process.</p><p> </p><p>In 2016/17 and 2017/18, £25 million was set aside for discretionary investment in new specialised services. This was determined by NHS England, who considered it an appropriate level of investment in the context of NHS England’s Specialised Commissioning functioning having to achieve overall efficiency savings of approximately 2.5% and 2.7% in 2016/17 and 2017/18 respectively in order to meet the financial pressures resulting from demographic growth and the legal requirement to fund all positive National Institute for Health and Care Excellence technology appraisals.</p><p> </p><p>The split in the overall funding available between the November and May prioritisation rounds is not fixed but determined each year based on the number and estimated cost of treatments being considered by the independently chaired Clinical Priorities Advisory Group (CPAG) in each round. Revealing the split risks revealing commercial in confidence information around pricing. Anything that is not prioritised in the November round has the opportunity to be considered at the May round therefore ensuring consideration against the full funding envelope for the financial year.</p><p> </p><p>Where manufacturers have requested the cover sheets of the policy propositions, they have received the CPAG summary report as presented at the May 2018 meeting from NHS England.</p><p> </p><p>The full scoring methodology that is used at all prioritisation meetings is published on the NHS England website. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf" target="_blank">https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf</a></p><p> </p><p>The outcome of the May 2018 prioritisation process through use of this methodology has been published as a ranked list of five prioritisation Levels. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/" target="_blank">https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/</a></p><p> </p><p>The impact assessments for all the treatments include a narrative about the estimated forecast financial implications for each item, based on the list price. These are published as part of the public consultation pack. The detailed costings are not shared as in many cases these are based on discount prices provided on a commercial in confidence basis.</p><p> </p><p>The methodology for relative prioritisation has been subject to legal advice as part of its development and implementation, and NHS England believes it complies with equalities legislation, the NHS Constitution and human rights legislation.</p><p> </p><p>NHS England routinely publishes the stakeholder engagement response report as part of consultation through policy development, but does not routinely publish any responses that arise as a result of public consultation.</p><p> </p><p>NHS England has no plans to introduce a revised decision-making process for ultra-orphan medicines as introduced in Scotland following the Montgomery Review. NHS England will continue to use the methodology for prioritisation that has previously been publicly consulted on.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 169109 169111 169112 169113 169114 169115 169116 169117 169118 question first answered 11/09/2018 16:26:10 answering member 4067 label Biography information for Steve Brine
	tabling member	1383 label Biography information for Mark Tami

964505

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when the (a) Clinical Priorities Advisory Group and (b) the Specialised Services Commissioning Committee plan to meet to discuss the next round of products for consideration by the relative prioritisation process.
	tabling member constituency	Alyn and Deeside
	tabling member printed	Mark Tami
	uin	169111
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The level of funding for products undergoing review by NHS England will be determined during the 2019/20 planning process.</p><p> </p><p>In 2016/17 and 2017/18, £25 million was set aside for discretionary investment in new specialised services. This was determined by NHS England, who considered it an appropriate level of investment in the context of NHS England’s Specialised Commissioning functioning having to achieve overall efficiency savings of approximately 2.5% and 2.7% in 2016/17 and 2017/18 respectively in order to meet the financial pressures resulting from demographic growth and the legal requirement to fund all positive National Institute for Health and Care Excellence technology appraisals.</p><p> </p><p>The split in the overall funding available between the November and May prioritisation rounds is not fixed but determined each year based on the number and estimated cost of treatments being considered by the independently chaired Clinical Priorities Advisory Group (CPAG) in each round. Revealing the split risks revealing commercial in confidence information around pricing. Anything that is not prioritised in the November round has the opportunity to be considered at the May round therefore ensuring consideration against the full funding envelope for the financial year.</p><p> </p><p>Where manufacturers have requested the cover sheets of the policy propositions, they have received the CPAG summary report as presented at the May 2018 meeting from NHS England.</p><p> </p><p>The full scoring methodology that is used at all prioritisation meetings is published on the NHS England website. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf" target="_blank">https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf</a></p><p> </p><p>The outcome of the May 2018 prioritisation process through use of this methodology has been published as a ranked list of five prioritisation Levels. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/" target="_blank">https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/</a></p><p> </p><p>The impact assessments for all the treatments include a narrative about the estimated forecast financial implications for each item, based on the list price. These are published as part of the public consultation pack. The detailed costings are not shared as in many cases these are based on discount prices provided on a commercial in confidence basis.</p><p> </p><p>The methodology for relative prioritisation has been subject to legal advice as part of its development and implementation, and NHS England believes it complies with equalities legislation, the NHS Constitution and human rights legislation.</p><p> </p><p>NHS England routinely publishes the stakeholder engagement response report as part of consultation through policy development, but does not routinely publish any responses that arise as a result of public consultation.</p><p> </p><p>NHS England has no plans to introduce a revised decision-making process for ultra-orphan medicines as introduced in Scotland following the Montgomery Review. NHS England will continue to use the methodology for prioritisation that has previously been publicly consulted on.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 169109 169110 169112 169113 169114 169115 169116 169117 169118 question first answered 11/09/2018 16:26:10 answering member 4067 label Biography information for Steve Brine
	tabling member	1383 label Biography information for Mark Tami

964509

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the compliance of the relative prioritisation process at NHS England with (a) equalities legislation, (b) the NHS Constitution and (c) human rights legislation.
	tabling member constituency	Alyn and Deeside
	tabling member printed	Mark Tami
	uin	169115
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The level of funding for products undergoing review by NHS England will be determined during the 2019/20 planning process.</p><p> </p><p>In 2016/17 and 2017/18, £25 million was set aside for discretionary investment in new specialised services. This was determined by NHS England, who considered it an appropriate level of investment in the context of NHS England’s Specialised Commissioning functioning having to achieve overall efficiency savings of approximately 2.5% and 2.7% in 2016/17 and 2017/18 respectively in order to meet the financial pressures resulting from demographic growth and the legal requirement to fund all positive National Institute for Health and Care Excellence technology appraisals.</p><p> </p><p>The split in the overall funding available between the November and May prioritisation rounds is not fixed but determined each year based on the number and estimated cost of treatments being considered by the independently chaired Clinical Priorities Advisory Group (CPAG) in each round. Revealing the split risks revealing commercial in confidence information around pricing. Anything that is not prioritised in the November round has the opportunity to be considered at the May round therefore ensuring consideration against the full funding envelope for the financial year.</p><p> </p><p>Where manufacturers have requested the cover sheets of the policy propositions, they have received the CPAG summary report as presented at the May 2018 meeting from NHS England.</p><p> </p><p>The full scoring methodology that is used at all prioritisation meetings is published on the NHS England website. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf" target="_blank">https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf</a></p><p> </p><p>The outcome of the May 2018 prioritisation process through use of this methodology has been published as a ranked list of five prioritisation Levels. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/" target="_blank">https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/</a></p><p> </p><p>The impact assessments for all the treatments include a narrative about the estimated forecast financial implications for each item, based on the list price. These are published as part of the public consultation pack. The detailed costings are not shared as in many cases these are based on discount prices provided on a commercial in confidence basis.</p><p> </p><p>The methodology for relative prioritisation has been subject to legal advice as part of its development and implementation, and NHS England believes it complies with equalities legislation, the NHS Constitution and human rights legislation.</p><p> </p><p>NHS England routinely publishes the stakeholder engagement response report as part of consultation through policy development, but does not routinely publish any responses that arise as a result of public consultation.</p><p> </p><p>NHS England has no plans to introduce a revised decision-making process for ultra-orphan medicines as introduced in Scotland following the Montgomery Review. NHS England will continue to use the methodology for prioritisation that has previously been publicly consulted on.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 169109 169110 169111 169112 169113 169114 169116 169117 169118 question first answered 11/09/2018 16:26:11 answering member 4067 label Biography information for Steve Brine
	tabling member	1383 label Biography information for Mark Tami

964510

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if NHS England will publish the full matrix scoring methodology used to determine the relative prioritisation of products undergoing review by the relative prioritisation process in May 2018.
	tabling member constituency	Alyn and Deeside
	tabling member printed	Mark Tami
	uin	169116
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The level of funding for products undergoing review by NHS England will be determined during the 2019/20 planning process.</p><p> </p><p>In 2016/17 and 2017/18, £25 million was set aside for discretionary investment in new specialised services. This was determined by NHS England, who considered it an appropriate level of investment in the context of NHS England’s Specialised Commissioning functioning having to achieve overall efficiency savings of approximately 2.5% and 2.7% in 2016/17 and 2017/18 respectively in order to meet the financial pressures resulting from demographic growth and the legal requirement to fund all positive National Institute for Health and Care Excellence technology appraisals.</p><p> </p><p>The split in the overall funding available between the November and May prioritisation rounds is not fixed but determined each year based on the number and estimated cost of treatments being considered by the independently chaired Clinical Priorities Advisory Group (CPAG) in each round. Revealing the split risks revealing commercial in confidence information around pricing. Anything that is not prioritised in the November round has the opportunity to be considered at the May round therefore ensuring consideration against the full funding envelope for the financial year.</p><p> </p><p>Where manufacturers have requested the cover sheets of the policy propositions, they have received the CPAG summary report as presented at the May 2018 meeting from NHS England.</p><p> </p><p>The full scoring methodology that is used at all prioritisation meetings is published on the NHS England website. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf" target="_blank">https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf</a></p><p> </p><p>The outcome of the May 2018 prioritisation process through use of this methodology has been published as a ranked list of five prioritisation Levels. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/" target="_blank">https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/</a></p><p> </p><p>The impact assessments for all the treatments include a narrative about the estimated forecast financial implications for each item, based on the list price. These are published as part of the public consultation pack. The detailed costings are not shared as in many cases these are based on discount prices provided on a commercial in confidence basis.</p><p> </p><p>The methodology for relative prioritisation has been subject to legal advice as part of its development and implementation, and NHS England believes it complies with equalities legislation, the NHS Constitution and human rights legislation.</p><p> </p><p>NHS England routinely publishes the stakeholder engagement response report as part of consultation through policy development, but does not routinely publish any responses that arise as a result of public consultation.</p><p> </p><p>NHS England has no plans to introduce a revised decision-making process for ultra-orphan medicines as introduced in Scotland following the Montgomery Review. NHS England will continue to use the methodology for prioritisation that has previously been publicly consulted on.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 169109 169110 169111 169112 169113 169114 169115 169117 169118 question first answered 11/09/2018 16:26:11 answering member 4067 label Biography information for Steve Brine
	tabling member	1383 label Biography information for Mark Tami

964511

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if NHS England will publish stakeholder responses to the public consultations on the draft policy propositions undergoing review by the relative prioritisation process in May 2018.
	tabling member constituency	Alyn and Deeside
	tabling member printed	Mark Tami
	uin	169117
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The level of funding for products undergoing review by NHS England will be determined during the 2019/20 planning process.</p><p> </p><p>In 2016/17 and 2017/18, £25 million was set aside for discretionary investment in new specialised services. This was determined by NHS England, who considered it an appropriate level of investment in the context of NHS England’s Specialised Commissioning functioning having to achieve overall efficiency savings of approximately 2.5% and 2.7% in 2016/17 and 2017/18 respectively in order to meet the financial pressures resulting from demographic growth and the legal requirement to fund all positive National Institute for Health and Care Excellence technology appraisals.</p><p> </p><p>The split in the overall funding available between the November and May prioritisation rounds is not fixed but determined each year based on the number and estimated cost of treatments being considered by the independently chaired Clinical Priorities Advisory Group (CPAG) in each round. Revealing the split risks revealing commercial in confidence information around pricing. Anything that is not prioritised in the November round has the opportunity to be considered at the May round therefore ensuring consideration against the full funding envelope for the financial year.</p><p> </p><p>Where manufacturers have requested the cover sheets of the policy propositions, they have received the CPAG summary report as presented at the May 2018 meeting from NHS England.</p><p> </p><p>The full scoring methodology that is used at all prioritisation meetings is published on the NHS England website. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf" target="_blank">https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf</a></p><p> </p><p>The outcome of the May 2018 prioritisation process through use of this methodology has been published as a ranked list of five prioritisation Levels. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/" target="_blank">https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/</a></p><p> </p><p>The impact assessments for all the treatments include a narrative about the estimated forecast financial implications for each item, based on the list price. These are published as part of the public consultation pack. The detailed costings are not shared as in many cases these are based on discount prices provided on a commercial in confidence basis.</p><p> </p><p>The methodology for relative prioritisation has been subject to legal advice as part of its development and implementation, and NHS England believes it complies with equalities legislation, the NHS Constitution and human rights legislation.</p><p> </p><p>NHS England routinely publishes the stakeholder engagement response report as part of consultation through policy development, but does not routinely publish any responses that arise as a result of public consultation.</p><p> </p><p>NHS England has no plans to introduce a revised decision-making process for ultra-orphan medicines as introduced in Scotland following the Montgomery Review. NHS England will continue to use the methodology for prioritisation that has previously been publicly consulted on.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 169109 169110 169111 169112 169113 169114 169115 169116 169118 question first answered 11/09/2018 16:26:11 answering member 4067 label Biography information for Steve Brine
	tabling member	1383 label Biography information for Mark Tami